

Wahl and O'Gorman  
USSN: 08/486,409  
Filed: June 7, 1995  
Page 6

21 80. (New) An isolated mammalian cell according to Claim 79, further comprising DNA encoding, and capable of expressing, in said cell, a FLP recombinase.

22 81. (New) An isolated mammalian cell according to Claim 79 wherein said first gene(s) of interest provide a readily analyzable marker feature upon expression.

23 82. (New) An isolated mammalian cell according to Claim 78 wherein said FLP recombination target site has the sequence:

5'-GAAGTTCCATTCTCTAGAAAGTATAGGAACCTTC-3'.

D 24 83. (New) An isolated mammalian cell according to Claim 79 further comprising a second DNA, wherein said second DNA comprises:

- (a) at least a second segment of said first gene of interest, or
- (b) at least a segment of a second gene of interest;

wherein said second DNA contains at least one FLP recombination target site; and wherein said second DNA, when combined in reading frame with said first DNA, provides a functional gene.

REMARKS

Courtesies extended to Applicants' representatives in telephonic interviews held February 13 and 14, 1997, are acknowledged with appreciation.

By the present communication, it is requested that claims 1-18 and 29-41 be canceled without prejudice, and new claims 60-83 be added in order to define

Wahl and O'Gorman  
USSN: 08/486,409  
Filed: June 7, 1995  
Page 7

Applicants' invention with greater particularity. New claims 60-83 correspond to prior claims 1-18 and 29-34, respectively. No new matter is introduced by the new claims as all new claim language is fully supported by the specification and original claims.

Accordingly, claims 60-83 are currently under examination.

In accordance with the Examiner's suggestion, the preamble for new claims 60-72 (corresponding to prior claims 1-13) reads "A composition that effects recombination in mammalian cells". As expressed in the telephonic interview held February 14, 1997, it is understood that new claims 60-72 read on any composition that contains the required elements, wherever such composition is located. Thus, it is not a requirement of new claims 60-72 that the required elements be combined *in vitro*, or prior to their introduction into a cell.

Also in accordance with the Examiner's suggestion, new claims 78-83 (corresponding to prior claims 29-34) have been written so as to read on isolated mammalian cells. Additionally, canceled claims 35-41, directed to transgenic, non-human mammals, have not been presented as new claims. Applicants therefore reserve their right to pursue these claims through a continuing application(s).


In view of the above amendments and remarks, reconsideration and favorable action on all pending claims are respectfully requested. If any minor matters remain to be resolved, the Examiner is invited to contact the undersigned at

Wahl and O'Gorman  
USSN: 08/486,409  
Filed: June 7, 1995  
Page 8

the telephone number set forth below so that a prompt disposition of this application can be achieved.

Respectfully submitted,

2/14/97  
Date



Gregory P. Raymer  
Registration No. 36,647  
Telephone No.: (619) 677-1496  
Facsimile No.: (619) 546-9392

GRAY CARY WARE & FREIDENRICH  
4365 Executive Drive, Suite 1600  
San Diego, CA 92121-2189